As the newest iterations of commercial and open-source molecular modeling tools and large-language models lower the barriers for implementing AI applications at biotechs, the challenge for management teams shifts to separating hype from substance among investment options within the pre-clinical and clinical development planning. This session will prioritize the AI-related productivity enhancements available now for biotechs already developing assets to help gather biochemical evidence more efficiently and advance to clinical results sooner.